Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist

BACKGROUND: ASC42 is a non-steroidal farnesoid X receptor agonist currently in clinical development for chronic liver diseases, such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) and primary biliary cirrhosis (PBC). OBJECTIVE: The objective of this study was to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Handan, Wu, Jinzi J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676321/
https://www.ncbi.nlm.nih.gov/pubmed/37919483
http://dx.doi.org/10.1007/s40268-023-00444-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676321/
https://www.ncbi.nlm.nih.gov/pubmed/37919483
http://dx.doi.org/10.1007/s40268-023-00444-4

Ejemplares similares